Yahoo · Nov 3, 2026
Bavarian Nordic secures four-year UK vaccine supply deal
MVA-BN is indicated for use in individuals from the age of two years considered at smallpox or mpox infection risk.
OTC · BVNRY
Bavarian Nordic A/S
Healthcare · Biotechnology
$12.33
Up+$0.26 (+2.15%)
Updated Nov 5, 2026, 4:01 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.34B
- P/E ratio
- 6.19
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 136
- Avg. volume
- 3.87K
Price performance · BVNRY
BVNRY price history
1M range · 0 trading sessions · Daily adjusted prices
BVNRY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BVNRY news
The latest Smart Investors Daily articles mentioning BVNRY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BVNRY research
Overview
Company profile and research snapshot.
Company profile
BAVARIAN NORDIC R/I S/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | JEFFERIES | Buy | — |
| Aug 21, 2026 | DNB CARNEGIE | Buy | — |
| May 19, 2026 | JEFFERIES | Buy | — |
| May 18, 2026 | JEFFERIES | Buy | — |
| May 13, 2026 | DNB CARNEGIE | Buy | — |
News briefing
Generated Nov 5, 2026, 3:18 PM
Why Is BVNRY Up Today?
Bavarian Nordic shares gained 2.15% today following the announcement of a significant four-year vaccine supply contract with the United Kingdom. The deal represents a meaningful revenue commitment and underscores continued demand for the company's vaccine portfolio in a major developed market.
Bottom line: Bavarian Nordic's four-year UK vaccine supply agreement provides encouraging evidence of sustained international demand and validates the company's market position. Investors should monitor contract details, financial guidance updates, and upcoming announcements from other markets to assess whether this deal signals a broader trend of government procurement momentum.
Yahoo · Nov 2, 2026
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed, reaching an aggregate amount of approximately DKK 250 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 750 million. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure through subsequen
Yahoo · Nov 2, 2026
Bavarian Nordic Awarded Multi-Year Vaccine Contract by UK Government
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the supply of MVA-BN®, a non-replicating vaccine indicated for the prevention of mpox and smallpox, further supporting the UK's long-term preparedness against emerging infectious disease threats. Under the four-year contract, Bavarian Nordic will supply MVA-BN through scheduled deliveries
Yahoo · Oct 27, 2026
Bavarian Nordic to Supply and Donate Vaccines for Global Mpox Emergency Stockpile
Bavarian Nordic donates 75,000 doses of MVA-BN® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile.Building emergency reserves is an important milestone in global mpox preparedness, helping ensure timely and equitable access to vaccines.This new initiative reflects Bavarian Nordic’s longstanding role as a trusted partner in global health security and its mission to protect people and communities, and save lives, through vaccines. COPENHAGEN, Denmark, October 27, 20
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
